Efficacy of melatonin, IL-25 and siIL-17B in tumorigenesis-associated properties of breast cancer cell lines

Gabriela Bottaro Gelaleti, Thaiz Ferraz Borin, Larissa Bazela Maschio-Signorini, Marina Gobbe Moschetta, Bruna Victorasso Jardim-Perassi, Guilherme Berto Calvinho, Mariana Castilho Facchini, Alicia M. Viloria-Petit, Debora Aparecida Pires de Campos Zuccari

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Mammary tumorigenesis can be modulated by melatonin, which has oncostatic action mediated by multiple mechanisms, including the inhibition of the activity of transcription factors such as NF-κB and modulation of interleukins (ILs) expression. IL-25 is an active cytokine that induces apoptosis in tumor cells due to differential expression of its receptor (IL-17RB). IL-17B competes with IL-25 for binding to IL-17RB in tumor cells, promoting tumorigenesis. This study purpose is to address the possibility of engaging IL-25/IL-17RB signaling to enhance the effect of melatonin on breast cancer cells. Breast cancer cell lines were cultured monolayers and 3D structures and treated with melatonin, IL-25, siIL-17B, each alone or in combination. Cell viability, gene and protein expression of caspase-3, cleaved caspase-3 and VEGF-A were performed by qPCR and immunofluorescence. In addition, an apoptosis membrane array was performed in metastatic cells. Treatments with melatonin and IL-25 significantly reduced tumor cells viability at 1 mM and 1 ng/mL, respectively, but did not alter cell viability of a non-tumorigenic epithelial cell line (MCF-10A). All treatments, alone and combined, significantly increased cleaved caspase-3 in tumor cells grown as monolayers and 3D structures (p < 0.05). Semi-quantitative analysis of apoptosis pathway proteins showed an increase of CYTO-C, DR6, IGFBP-3, IGFBP-5, IGFPB-6, IGF-1, IGF-1R, Livin, P21, P53, TNFRII, XIAP and hTRA proteins and reduction of caspase-3 (p < 0.05) after melatonin treatment. All treatments reduced VEGF-A protein expression in tumor cells (p < 0.05). Our results suggest therapeutic potential, with oncostatic effectiveness, pro-apoptotic and anti-angiogenic properties for melatonin and IL-25-driven signaling in breast cancer cells.

Original languageEnglish (US)
Pages (from-to)98-109
Number of pages12
JournalLife sciences
Volume183
DOIs
StatePublished - Aug 15 2017

Fingerprint

Interleukin-17
Melatonin
Carcinogenesis
Cells
Breast Neoplasms
Cell Line
Caspase 3
Interleukins
Tumors
Cell Survival
Neoplasms
Apoptosis
Vascular Endothelial Growth Factor A
X-Linked Inhibitor of Apoptosis Protein
Interleukin Receptors
Insulin-Like Growth Factor Binding Protein 5
Therapeutics
Insulin-Like Growth Factor Binding Protein 3
Proteins
Monolayers

Keywords

  • Apoptosis
  • Breast cancer
  • Interleukin-17B
  • Interleukin-17E
  • Interleukin-25
  • Melatonin
  • VEGF

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Gelaleti, G. B., Borin, T. F., Maschio-Signorini, L. B., Moschetta, M. G., Jardim-Perassi, B. V., Calvinho, G. B., ... de Campos Zuccari, D. A. P. (2017). Efficacy of melatonin, IL-25 and siIL-17B in tumorigenesis-associated properties of breast cancer cell lines. Life sciences, 183, 98-109. https://doi.org/10.1016/j.lfs.2017.06.013

Efficacy of melatonin, IL-25 and siIL-17B in tumorigenesis-associated properties of breast cancer cell lines. / Gelaleti, Gabriela Bottaro; Borin, Thaiz Ferraz; Maschio-Signorini, Larissa Bazela; Moschetta, Marina Gobbe; Jardim-Perassi, Bruna Victorasso; Calvinho, Guilherme Berto; Facchini, Mariana Castilho; Viloria-Petit, Alicia M.; de Campos Zuccari, Debora Aparecida Pires.

In: Life sciences, Vol. 183, 15.08.2017, p. 98-109.

Research output: Contribution to journalArticle

Gelaleti, GB, Borin, TF, Maschio-Signorini, LB, Moschetta, MG, Jardim-Perassi, BV, Calvinho, GB, Facchini, MC, Viloria-Petit, AM & de Campos Zuccari, DAP 2017, 'Efficacy of melatonin, IL-25 and siIL-17B in tumorigenesis-associated properties of breast cancer cell lines', Life sciences, vol. 183, pp. 98-109. https://doi.org/10.1016/j.lfs.2017.06.013
Gelaleti GB, Borin TF, Maschio-Signorini LB, Moschetta MG, Jardim-Perassi BV, Calvinho GB et al. Efficacy of melatonin, IL-25 and siIL-17B in tumorigenesis-associated properties of breast cancer cell lines. Life sciences. 2017 Aug 15;183:98-109. https://doi.org/10.1016/j.lfs.2017.06.013
Gelaleti, Gabriela Bottaro ; Borin, Thaiz Ferraz ; Maschio-Signorini, Larissa Bazela ; Moschetta, Marina Gobbe ; Jardim-Perassi, Bruna Victorasso ; Calvinho, Guilherme Berto ; Facchini, Mariana Castilho ; Viloria-Petit, Alicia M. ; de Campos Zuccari, Debora Aparecida Pires. / Efficacy of melatonin, IL-25 and siIL-17B in tumorigenesis-associated properties of breast cancer cell lines. In: Life sciences. 2017 ; Vol. 183. pp. 98-109.
@article{3663789502c44b7e96f29d2ab2d273e8,
title = "Efficacy of melatonin, IL-25 and siIL-17B in tumorigenesis-associated properties of breast cancer cell lines",
abstract = "Mammary tumorigenesis can be modulated by melatonin, which has oncostatic action mediated by multiple mechanisms, including the inhibition of the activity of transcription factors such as NF-κB and modulation of interleukins (ILs) expression. IL-25 is an active cytokine that induces apoptosis in tumor cells due to differential expression of its receptor (IL-17RB). IL-17B competes with IL-25 for binding to IL-17RB in tumor cells, promoting tumorigenesis. This study purpose is to address the possibility of engaging IL-25/IL-17RB signaling to enhance the effect of melatonin on breast cancer cells. Breast cancer cell lines were cultured monolayers and 3D structures and treated with melatonin, IL-25, siIL-17B, each alone or in combination. Cell viability, gene and protein expression of caspase-3, cleaved caspase-3 and VEGF-A were performed by qPCR and immunofluorescence. In addition, an apoptosis membrane array was performed in metastatic cells. Treatments with melatonin and IL-25 significantly reduced tumor cells viability at 1 mM and 1 ng/mL, respectively, but did not alter cell viability of a non-tumorigenic epithelial cell line (MCF-10A). All treatments, alone and combined, significantly increased cleaved caspase-3 in tumor cells grown as monolayers and 3D structures (p < 0.05). Semi-quantitative analysis of apoptosis pathway proteins showed an increase of CYTO-C, DR6, IGFBP-3, IGFBP-5, IGFPB-6, IGF-1, IGF-1R, Livin, P21, P53, TNFRII, XIAP and hTRA proteins and reduction of caspase-3 (p < 0.05) after melatonin treatment. All treatments reduced VEGF-A protein expression in tumor cells (p < 0.05). Our results suggest therapeutic potential, with oncostatic effectiveness, pro-apoptotic and anti-angiogenic properties for melatonin and IL-25-driven signaling in breast cancer cells.",
keywords = "Apoptosis, Breast cancer, Interleukin-17B, Interleukin-17E, Interleukin-25, Melatonin, VEGF",
author = "Gelaleti, {Gabriela Bottaro} and Borin, {Thaiz Ferraz} and Maschio-Signorini, {Larissa Bazela} and Moschetta, {Marina Gobbe} and Jardim-Perassi, {Bruna Victorasso} and Calvinho, {Guilherme Berto} and Facchini, {Mariana Castilho} and Viloria-Petit, {Alicia M.} and {de Campos Zuccari}, {Debora Aparecida Pires}",
year = "2017",
month = "8",
day = "15",
doi = "10.1016/j.lfs.2017.06.013",
language = "English (US)",
volume = "183",
pages = "98--109",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Efficacy of melatonin, IL-25 and siIL-17B in tumorigenesis-associated properties of breast cancer cell lines

AU - Gelaleti, Gabriela Bottaro

AU - Borin, Thaiz Ferraz

AU - Maschio-Signorini, Larissa Bazela

AU - Moschetta, Marina Gobbe

AU - Jardim-Perassi, Bruna Victorasso

AU - Calvinho, Guilherme Berto

AU - Facchini, Mariana Castilho

AU - Viloria-Petit, Alicia M.

AU - de Campos Zuccari, Debora Aparecida Pires

PY - 2017/8/15

Y1 - 2017/8/15

N2 - Mammary tumorigenesis can be modulated by melatonin, which has oncostatic action mediated by multiple mechanisms, including the inhibition of the activity of transcription factors such as NF-κB and modulation of interleukins (ILs) expression. IL-25 is an active cytokine that induces apoptosis in tumor cells due to differential expression of its receptor (IL-17RB). IL-17B competes with IL-25 for binding to IL-17RB in tumor cells, promoting tumorigenesis. This study purpose is to address the possibility of engaging IL-25/IL-17RB signaling to enhance the effect of melatonin on breast cancer cells. Breast cancer cell lines were cultured monolayers and 3D structures and treated with melatonin, IL-25, siIL-17B, each alone or in combination. Cell viability, gene and protein expression of caspase-3, cleaved caspase-3 and VEGF-A were performed by qPCR and immunofluorescence. In addition, an apoptosis membrane array was performed in metastatic cells. Treatments with melatonin and IL-25 significantly reduced tumor cells viability at 1 mM and 1 ng/mL, respectively, but did not alter cell viability of a non-tumorigenic epithelial cell line (MCF-10A). All treatments, alone and combined, significantly increased cleaved caspase-3 in tumor cells grown as monolayers and 3D structures (p < 0.05). Semi-quantitative analysis of apoptosis pathway proteins showed an increase of CYTO-C, DR6, IGFBP-3, IGFBP-5, IGFPB-6, IGF-1, IGF-1R, Livin, P21, P53, TNFRII, XIAP and hTRA proteins and reduction of caspase-3 (p < 0.05) after melatonin treatment. All treatments reduced VEGF-A protein expression in tumor cells (p < 0.05). Our results suggest therapeutic potential, with oncostatic effectiveness, pro-apoptotic and anti-angiogenic properties for melatonin and IL-25-driven signaling in breast cancer cells.

AB - Mammary tumorigenesis can be modulated by melatonin, which has oncostatic action mediated by multiple mechanisms, including the inhibition of the activity of transcription factors such as NF-κB and modulation of interleukins (ILs) expression. IL-25 is an active cytokine that induces apoptosis in tumor cells due to differential expression of its receptor (IL-17RB). IL-17B competes with IL-25 for binding to IL-17RB in tumor cells, promoting tumorigenesis. This study purpose is to address the possibility of engaging IL-25/IL-17RB signaling to enhance the effect of melatonin on breast cancer cells. Breast cancer cell lines were cultured monolayers and 3D structures and treated with melatonin, IL-25, siIL-17B, each alone or in combination. Cell viability, gene and protein expression of caspase-3, cleaved caspase-3 and VEGF-A were performed by qPCR and immunofluorescence. In addition, an apoptosis membrane array was performed in metastatic cells. Treatments with melatonin and IL-25 significantly reduced tumor cells viability at 1 mM and 1 ng/mL, respectively, but did not alter cell viability of a non-tumorigenic epithelial cell line (MCF-10A). All treatments, alone and combined, significantly increased cleaved caspase-3 in tumor cells grown as monolayers and 3D structures (p < 0.05). Semi-quantitative analysis of apoptosis pathway proteins showed an increase of CYTO-C, DR6, IGFBP-3, IGFBP-5, IGFPB-6, IGF-1, IGF-1R, Livin, P21, P53, TNFRII, XIAP and hTRA proteins and reduction of caspase-3 (p < 0.05) after melatonin treatment. All treatments reduced VEGF-A protein expression in tumor cells (p < 0.05). Our results suggest therapeutic potential, with oncostatic effectiveness, pro-apoptotic and anti-angiogenic properties for melatonin and IL-25-driven signaling in breast cancer cells.

KW - Apoptosis

KW - Breast cancer

KW - Interleukin-17B

KW - Interleukin-17E

KW - Interleukin-25

KW - Melatonin

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=85021670148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021670148&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2017.06.013

DO - 10.1016/j.lfs.2017.06.013

M3 - Article

VL - 183

SP - 98

EP - 109

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

ER -